6990 — Sichuan Kelun-Biotech Biopharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00- HK$41.43bn
- HK$38.80bn
- CNY1.54bn
Annual income statement for Sichuan Kelun-Biotech Biopharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 32.3 | 804 | 1,540 |
| Cost of Revenue | |||
| Gross Profit | 11.8 | 527 | 759 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 810 | 1,222 | 1,924 |
| Operating Profit | -777 | -419 | -383 |
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | -890 | -567 | -468 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -890 | -616 | -574 |
| Net Income Before Extraordinary Items | |||
| Net Income | -890 | -616 | -574 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -890 | -616 | -574 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -4.12 | -2.84 | -2.53 |